Inspira to Publish HYLA Clinical Results in Q4 2024

Ticker: IINNW · Form: 6-K · Filed: Aug 28, 2024 · CIK: 1837493

Inspira Technologies Oxy B.H.N. LTD 6-K Filing Summary
FieldDetail
CompanyInspira Technologies Oxy B.H.N. LTD (IINNW)
Form Type6-K
Filed DateAug 28, 2024
Risk Levelmedium
Pages1
Reading Time1 min
Sentimentneutral

Sentiment: neutral

Topics: clinical-results, medical-device, filing-update

TL;DR

Inspira dropping HYLA clinical results Q4 '24. Big news for their tech.

AI Summary

Inspira Technologies Oxy B.H.N. Ltd. announced on August 28, 2024, that it will publish clinical results for its HYLA device in the fourth quarter of 2024. This update was provided in a Form 6-K filing with the SEC.

Why It Matters

The release of clinical results for the HYLA device is a key milestone that could impact the company's future product development and market positioning in the medical technology sector.

Risk Assessment

Risk Level: medium — The company's reliance on the successful development and market acceptance of its HYLA device presents a significant risk.

Key Players & Entities

FAQ

When will Inspira Technologies publish the clinical results for its HYLA device?

Inspira Technologies plans to publish the HYLA clinical results in the fourth quarter of 2024.

What type of filing is this report?

This is a Form 6-K report, which is a report of a foreign private issuer.

What is the primary business of Inspira Technologies Oxy B.H.N. Ltd. based on SIC code?

Based on the Standard Industrial Classification (SIC) code 3841, the company is involved in Surgical & Medical Instruments & Apparatus.

Where is Inspira Technologies Oxy B.H.N. Ltd. located?

The company's principal executive office is located at 2 Ha-Tidhar St., Ra'anana 4366504, Israel.

What is the filing date of this report?

The filing date of this report is August 28, 2024.

Filing Stats: 304 words · 1 min read · ~1 pages · Grade level 8.9 · Accepted 2024-08-28 09:05:33

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Inspira Technologies Oxy B.H.N. Ltd. Date: August 28, 2024 By: /s/ Dagi Ben-Noon Name: Dagi Ben-Noon Title: Chief Executive Officer 2

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing